Targeted Oncology

New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRC

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
The American Journal of Managed Care

Amivantamab Plus Chemotherapy Delivers Durable Responses in RAS/BRAF Wild-Type mCRC: Filippo Pietrantonio, MD

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...
The American Journal of Managed Care

GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin

Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing significant efficacy. These results were presented during the press briefing ahead of the 2026 ...
Health And Pharma

Amivantamab Plus Chemotherapy Shows Promising Long-Term Responses in Colorectal Cancer

Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved ...
Seeking Alpha

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

- Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (CRDF), a clinical-stage biotechnology company leveraging ...
Business Insider

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
ascopubs.org

Sensitizing K-Ras G12D mutant colorectal patient-derived organoids via ferroptosis pathway.

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...